Corcept Therapeutics (CORT) FCF Margin (2012 - 2026)

Corcept Therapeutics has disclosed FCF Margin across 15 years of filings, most recently posting 10.29% for Q1 2026.

• FCF Margin for Q1 2026 came in at 10.29%, down 1326.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.62% (down 1021.0% YoY), and the FY2025 annual result was 18.62%, down 1043.0% from the prior year.
• FCF Margin came in at 10.29% for Q1 2026 at Corcept Therapeutics, down from 19.0% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 42.78% in Q3 2023 to a low of 10.29% in Q1 2026.
• The 5-year median for FCF Margin is 24.89% (2024), against an average of 23.61%.
• Across the five-year window, FCF Margin slumped 3085 bps in 2022 and soared 2887 bps in 2024, its largest moves.
• Corcept Therapeutics' FCF Margin stood at 32.37% in 2022, then slumped by 87 bps to 4.08% in 2023, then surged by 707 bps to 32.95% in 2024, then tumbled by 42 bps to 19.0% in 2025, then slumped by 154 bps to 10.29% in 2026.
• The last three FCF Margin figures came in at 10.29% (Q1 2026), 19.0% (Q4 2025), and 26.24% (Q3 2025), per Business Quant data.